In a multivariate analysis that included prophylactic G-CSF, CAR T construct, bridging therapy, ANC, platelets, and LDH, both CAR T construct (axicabtagene ciloleucel, HR 3.48, 95% CI 1.12–10.84, P = 0.03) and prophylactic G-CSF exposure retained significance for an increased risk of grade ≥2 CRS (HR 2.15, 95% CI 1.11–4.18, P = 0.02). This evidence concerns the gene CSF3 and congenital rubella syndrome.